Why Your Vitamin B12 Injection Remains Prescription-Only in the UK

The regulatory status of injectable B12 is a source of frustration for many, particularly those advocating for greater patient autonomy. Here, our Chief Executive Officer, Katrina Burchell breaks down the legal and clinical reasons behind the current classification and highlights the crucial work being done by the Pernicious Anaemia Society to improve care.

The Context

First let’s set the scene of why and how medicines are classified in the UK and the circumstances in which a change might be made.

Overarching Principle

The fundamental principle of regulation of medicines is to optimise timely access to effective treatments while reducing the risk of harm from improper use. The classification of a medicine is based on the level of health professional input needed to diagnose and manage the conditions for which the product is used.

Three Legal Classifications

UK medicines fall into one of three legal categories:

1. Prescription-Only Medicine (POM):

• Can only be obtained with a valid prescription from an authorised health professional.
• Generally intended for conditions that require professional diagnosis and management (this would include Pernicious Anaemia, an autoimmune disease).

2. Pharmacy Medicine (P):

• Can be bought only from a pharmacy and must be supplied by or under the supervision of a pharmacist.
• Often used for short-term, readily identifiable medical conditions. Pharmacists ensure the medicine is appropriate, offer advice, and check if the person needs to see a doctor.

3. General Sales List Medicines (GSL):

• Can be purchased from general retail outlets (e.g., supermarkets, corner shops) without the supervision of a pharmacist.
• For common, easily recognised ailments that are usually short-lived and cause few side effects in normal use.
• P and GSL medicines are collectively known as Over-The-Counter (OTC) medicines.

Types of Reclassification (Switching)

The legal status of a medicine is changed when there is growing confidence in the medicine’s action and safety profile. The most common switches are:

• POM to P: Occurs when the medicine no longer meets the legal criteria requiring prescription control (e.g., the risk of misuse or danger to human health without medical supervision is minimal).
• P to GSL: Appropriate when the medicine can be sold “with reasonable safety” outside of a pharmacy environment, meaning the hazard to health, risk of misuse, or need for special precautions is small, and wider sale is a convenience. There may still be restrictions on the number of packets sold at one time for example.

Evidence and Procedure

Any classification change request must be supported by strong evidence that demonstrates the risk to the public will be adequately managed. Required evidence may include clinical studies, extensive post-marketing use data, expert advice, and the views of relevant health professionals and public associations.

The MHRA (Medicines and Healthcare products Regulatory Agency)

has two main application procedures:

1. Simple Reclassification: This is a straightforward and quick procedure based on an analogous product (a medicinal product already on the UK market with the same active ingredient, route of administration, use, and a similar or higher strength/dosage).
2. Major Reclassification: This detailed, stepwise procedure applies to applications that “break new ground,” such as a new type of medicine or condition being considered for a classification change.

During the assessment process for major reclassifications, the MHRA may:

• Take advice from its expert advisory body, the Commission on Human Medicines (CHM).
• Consult a ‘stakeholder group’ comprising healthcare professionals and public representatives.
• Run a 21-day public consultation to gather public views.

It is important to note, however, that in the case of medicines administered by injection, the MHRA is governed also by the foundational Medicines Act 1968 (now largely embodied in the Human Medicines Regulations 2012). This legislation firmly states that virtually all medicines administered by injection are automatically designated as Prescription-Only Medicines (POM), creating a powerful legal hurdle that cannot be overcome by simply demonstrating safety through clinical trials alone.

Most of the product licences, or marketing authorities as they are called in the UK, for hydroxocobalamin date from the 1990s when the requirement for evidence was different than it is now. It is frustrating to us as Patient Advocates that initial evidence relied on was not at that time suitably researched or understood and now, 30 years on, of course, we know so much more.

The Legal Hurdles: Why Injectable Hydroxocobalamin is a POM

For patients, the legal classification of hydroxocobalamin often feels illogical and deeply frustrating. They reason that hydroxocobalamin is not a psychoactive substance or a synthetic chemical ‘drug’; it is a vitamin, a nutrient essential for every cell in the body. People who have intrinsic factor get it from eating animal products but people with Pernicious Anaemia cannot absorb it from diet. Perhaps recklessly, I’m going to suggest that a comparison might be drawn to medicinal cannabis. While cannabis is a natural plant product, its legal classification is based on its psychoactive compounds and the strict control required over its use and supply. Similarly, B12 is classified not for its chemical nature (a vitamin) but for the high-risk administration route (injection) and the severity of the condition (Pernicious Anaemia) it treats. The patient frustration lies in feeling controlled by a law that treats a life-sustaining nutrient as if it were a high-risk pharmaceutical, simply because of how it is delivered.

If you have ever been told by your doctor or nurse that you are “addicted” to B12, you will hopefully forgive my tongue in cheek loose analogy with cannabis.

Current UK law generally restricts all injectable products to POM status. For a medicine to be ‘switched’ to non-prescription status, it must be proven safe to use without medical supervision. The MHRA views the technical skill and potential risks associated with self-injecting as a major contributing factor that prevents a switch.

Attempts to reclassify injectable B12 to a Pharmacy (P) or General Sales List (GSL) medicine have consistently met resistance from the Medicines and Healthcare products Regulatory Agency and the government, based on two key legal criteria outlined in the Human Medicines Regulations 2012:

1. The Route of Administration

The most significant barrier is that hydroxocobalamin is licensed for parenteral administration—meaning it must be given by injection (Intramuscular, IM). In practice a GP or nurse may administer off-licence by giving a sub-cutaneous (under the skin, SC) injection but it is important to remember that the GP makes their own decision and takes their own accountability and reliability if they go “off-licence”. They must be able to prove that they are prescribing off licence in the patient’s best interests.

There are biochemical reasons that suggest an intramuscular (IM) injection delivers hydroxocobalamin to the bloodstream more rapidly and potentially more effectively than the subcutaneous (SC) route. However, patient experience is mixed: while some members report no difference between the two methods, others find they do not achieve the same symptom resolution with SC injections. Critically, there is no rigorous, comparative research to definitively prove the methods are equally effective or interchangeable. Closing this knowledge gap is a priority for the Society, as an SC injection is potentially less painful and significantly easier to self-administer, offering clear opportunities for enhanced patient autonomy and improved long-term outcomes.

2. The Need for Clinical Management

Hydroxocobalamin injections are licensed to treat conditions, such as Pernicious Anaemia, that require an initial diagnosis and ongoing clinical monitoring by a physician.

B12 deficiency can lead to severe and potentially irreversible neurological damage if misdiagnosed or inadequately treated. Regulators are concerned that making the medicine widely available could lead to:

• Misdiagnosis: Patients self-treating a different, underlying condition.
• Delayed Treatment: Masking symptoms while the neurological damage progresses.

Since the condition it treats demands professional diagnosis and lifelong oversight, the legal requirement for a doctor’s supervision remains in place.

Now the above explanation will be a ‘red rag to a bull’ for many patients reading this Blog. The consistently reported poor diagnosis and treatment experience encountered in UK Primary Care by people with a diagnosis, or symptomatic of, Pernicious Anaemia in the UK is well documented and reported on in research carried out and published by the Pernicious Anaemia Society. Regardless of what we each think of our personal journey and experience, the reality is “the powers that be” insist it is a medical condition which requires professional diagnosis and treatment.

I agree. And the position of the Pernicious Anaemia Society has always been that PA is more than just B12 deficiency. It is an autoimmune disease with other comorbidity diseases and an increased risk of other conditions which should be properly monitored and managed even if we are a very long way from that being the reality in the UK. The fundamental issue is the lack of education, awareness and respect demonstrated by many GPs to patients seeking a diagnosis or treatment. It is a huge hurdle we and others in the B12 community are working on to overcome.

A GSL Switch is Unlikely in the Current Climate

Despite a recent drive by the Department of Health and Social Care (DHSC) to encourage the reclassification of certain medicines (like those for pain, sleep aids, and skin conditions) to P or GSL status, a switch for injectable B12 is not on the cards.

The medicines being considered for reclassification are typically those that treat common, self-limiting conditions or those where the risk can be managed with pharmacy intervention.

Some examples of recent POM to P “switches” include:

• Sildenafil (e.g., Viagra Connect – 50mg tablets):
  ◦ Condition: Erectile dysfunction (ED) in adult men.
  ◦ Reasoning: This was a highly significant switch in 2017. The MHRA determined that the product could be safely supplied following a consultation with a pharmacist, thereby making it more accessible while helping to prevent illegal online sales and encouraging men to seek advice on what could be a serious underlying health condition.
• Dovonex (Calcipotriol 50 micrograms/g ointment):
  ◦ Condition: Psoriasis.
  ◦ Reasoning: The reclassification was approved to allow pharmacists to supply the product without a prescription for the initial treatment of stable, mild-to-moderate plaque psoriasis in adults, increasing self-care options.

Other areas for focus in the past and more recently have been Short-term Sleep Aids, Pain Management (e.g., certain medicines for migraine or joint pain), Skin Conditions (e.g., treatments for acne, eczema, and psoriasis) and Women’s Health Conditions (e.g., treatments for heavy periods or intimate fungal infections)

Again, it is frustrating here for people with PA to see that these “chemical drug solutions” are freely available while, for them, a life changing and life saving vitamin solution is heavily restricted. Remember though that the restriction is about the delivery by injection. The products which have changed are not injectable.

This is the reason why the fundamental criteria for injectable B12—the route of administration and the severity of the underlying condition—have not changed. Without a substantial change in UK medicines law or the development of a fully proven and licensed non-injectable alternative for malabsorption conditions like PA, the injection will remain a Prescription-Only Medicine.